Projects and Grants per year
Personal profile
Research Interests
Dr. Zinner’s work and research interests include:
- Developing neoadjuvant and induction chemo-immune and molecularly targeted therapy regimens in surgery and radiation in the treatment of lung and head and neck cancer patients to reduce long-term morbidity and increase overall survival.
- Working toward the development of a KRAS program in lung cancer, which Kentucky and the region are especially well-placed to lead nationally.
- Increasing the odds of long-term survival and well-being in newly diagnosed and recurrent advanced stage lung and head and neck cancer using novel combinations of existing or newer therapeutics.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Post Doctoral Fellow, University Of Texas Health Science Center
1999
Residency, Thomas Jefferson University
1996
Doctor of Medicine, Georgetown University
1993
Bachelor of Arts, University Of California - Berkeley
1986
Fingerprint
- 1 Similar Profiles
-
22-LUN-130-MSD (MK-7339 -013-03): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Conc
Merck Sharp & Dohme Corporation
1/13/23 → 10/25/25
Project: Research project
-
22-LUN-127-AZ: A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Fo
AstraZeneca Pharmaceuticals LP (domestic)
5/12/22 → 2/6/25
Project: Research project
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Mirati Therapeutics Incorporated
11/20/20 → 8/16/25
Project: Research project
-
A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK -RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent
Arnold, S., Kejner, A. & Zinner, R.
11/2/20 → 7/26/25
Project: Research project